HPVC2016-108 Biopharmaceutical - Infliximab

Current Contract

Contract Start Date
01 Feb 2016
Contract End Date
30 Apr 2024
Option Periods


For the provision of Biopharmaceutical Infliximab

Additional Information

Contract Details

The Principal Period commenced on 1st of February 2016 and ran until 30th of April 2018.

The first Contract Option period of two years was executed – effective from 1 May 2018 until 30 April 2020.

The second Contract Option of two years has been executed – effective from 1 May 2020 until 30 April 2022.

Contract has been extended - effective 1 May 2022 until 30 April 2024.

Option Periods Remaining


Sales Report Template

(You must be a registered supplier on the HPV website and have logged in to access the link above for the new reporting template.)